8-K: VSee Health Amends Convertible Note, Sets Conversion Price at $0.75

VSee Health, Inc. has amended its senior secured convertible promissory note, revising the conversion price to $0.75 per share.

Summary

• VSee Health, Inc. (the Company) entered into Amendment No. 1 (the Amendment) to its senior secured convertible promissory note (the Note) on October 21, 2025.
• The Note, originally issued on September 30, 2024, had a principal amount of $2,222,222 and was with an accredited and institutional investor, Ascent Partners Fund LLC (the Holder).
• The Amendment revises the definition of the 'Conversion Price' as set forth in the Note to be equal to $0.75.
• All other terms, covenants, and conditions of the Note remain in full force and effect.
• The Company Parties reaffirmed all obligations and liabilities under the Transaction Documents and confirmed that all Liens granted continue to secure the Obligations.
• The Company Parties released the Purchaser and Purchaser Parties from any and all claims and losses.

Sentiment

Score: 4

Explanation: The amendment is a procedural update to a financing agreement. While it clarifies terms, the change in conversion price to $0.75, if lower than the previous undisclosed price, would be dilutive for existing shareholders. The release of claims by the Company also suggests a concession. Without knowing the prior conversion price, a definitive positive or negative sentiment is difficult, leaning slightly negative due to potential dilution and concessions.

Positives

• The amendment clarifies and formalizes the terms of the existing senior secured convertible promissory note, providing certainty for both the Company and the Holder.
• The Company's reaffirmation of its obligations and the security interests under the Transaction Documents may provide stability to the lender and ensure continued financing terms.

Negatives

• The revision of the Conversion Price to $0.75, if lower than the previous price (which is not disclosed in the filing), would result in increased potential dilution for existing shareholders upon conversion of the note.
• The Company Parties' agreement to release the Purchaser and Purchaser Parties from 'any and all claims and from any other Losses' could indicate a concession made by the Company or limit its future recourse for past issues.

Risks

• Potential for significant dilution for existing shareholders if the convertible note is converted at the new $0.75 price, especially if this represents a reduction from a prior, higher conversion price.
• The existence of a senior secured convertible promissory note implies a debt obligation that needs to be serviced or converted, carrying inherent financial risk for the Company.
• The Company's agreement to release the Purchaser from claims and losses could expose the Company to unrecoverable past issues or limit its ability to pursue future claims.
• The Purchaser retains the discretion to terminate the amendment if the 'Amendment Effective Date' (payment of all obligations due) does not occur within two business days, posing a short-term operational and financing risk.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the Company's future financial performance or strategic direction beyond the terms of the amended note.

Management Comments

• Imoigele Aisiku, Co-Chief Executive Officer of VSee Health, Inc., signed the Current Report on Form 8-K.
• Imoigele Aisiku, Chief Executive Officer of IDoc Virtual Telehealth Solutions, Inc., signed the Amendment No. 1.
• Milton Chen, Chief Executive Officer of VSee Lab, Inc., signed the Amendment No. 1.

Industry Context

VSee Health, Inc. operates in the telehealth sector, as indicated by its subsidiary IDoc Virtual Telehealth Solutions, Inc. The amendment of a convertible note is a common financing mechanism for growth-stage companies, particularly in sectors requiring ongoing capital investment and technological development.

Legal Proceedings

• The Company Parties released the Purchaser and Purchaser Parties from 'any and all claims and from any other Losses,' which could be a settlement or a preventative measure against potential legal disputes.

Stakeholder Impact

• Shareholders: Potential for increased dilution if the $0.75 conversion price is lower than the previous price, leading to a larger number of shares issued upon conversion.
• Creditors/Note Holder (Ascent Partners Fund LLC): The amendment clarifies the conversion terms and reaffirms the security of the note, potentially strengthening their position.
• Company: Secures the terms of its existing debt financing, but potentially at the cost of increased future dilution and a release of claims.

Next Steps

• The 'Amendment Effective Date' requires the payment of all Obligations due on or before, but after giving effect to, the effective date of this amendment.
• The Purchaser may, in its sole discretion, elect to terminate the amendment if the Amendment Effective Date has not occurred within two Business Days after October 21, 2025.

Key Dates

Recommendation

The filing details an amendment to a convertible note, specifically adjusting the conversion price. While the new conversion price of $0.75 could imply increased dilution if it's lower than the previous price (which is not disclosed), the amendment also reaffirms the company's obligations and the secured nature of the note. Without further context on the company's operational performance, the full financial implications of this specific conversion price change, or the prior conversion price, a definitive 'buy' or 'sell' recommendation is premature. Investors should 'hold' and monitor future filings for more comprehensive financial results and the impact of this amendment. The release of claims by the company also warrants caution.

Keywords

VSee Health, convertible note, SEC filing, 8-K, financing, dilution, corporate governance, Ascent Partners Fund, promissory note, securities purchase agreement, conversion price, telehealth